Shire is planning a late-stage study for its SHP655 drug to treat a rare enzyme deficiency.
- PR Newswire•yesterday
Shire Receives FDA Fast Track Designation for Recombinant ADAMTS13 (SHP655) for Treatment of Hereditary Thrombotic Thrombocytopenic Purpura
Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for recombinant ADAMTS13 (SHP655 - historically known as BAX930) for treatment of acute episodes of hereditary thrombotic thrombocytopenic purpura (hTTP) in patients with a constitutional deficiency of the von Willebrand factor-cleaving (VWF) protease ADAMTS13. FDA's Fast Track designation is supported by preclinical data and a Phase 1 study.
- Zacks•2 days ago
Let's see if Shire plc (SHPG) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
SHPG : Summary for Shire plc - Yahoo Finance
Shire plc (SHPG)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||174.24 x 100|
|Ask||174.32 x 100|
|Day's Range||173.56 - 175.40|
|52 Week Range||161.09 - 209.22|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||139.98|
|Dividend & Yield||0.91 (0.53%)|
|1y Target Est||N/A|